GeneDx (WGS) Competitors $100.59 -2.60 (-2.52%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$101.24 +0.66 (+0.65%) As of 08:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock WGS vs. HIMS, OPCH, GH, RDNT, SHC, SGRY, BTSG, PRVA, CON, and LFSTShould you be buying GeneDx stock or one of its competitors? The main competitors of GeneDx include Hims & Hers Health (HIMS), Option Care Health (OPCH), Guardant Health (GH), RadNet (RDNT), Sotera Health (SHC), Surgery Partners (SGRY), BrightSpring Health Services (BTSG), Privia Health Group (PRVA), Concentra Group Holdings Parent (CON), and LifeStance Health Group (LFST). These companies are all part of the "healthcare" industry. GeneDx vs. Hims & Hers Health Option Care Health Guardant Health RadNet Sotera Health Surgery Partners BrightSpring Health Services Privia Health Group Concentra Group Holdings Parent LifeStance Health Group GeneDx (NASDAQ:WGS) and Hims & Hers Health (NYSE:HIMS) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, community ranking, institutional ownership and earnings. Do analysts prefer WGS or HIMS? GeneDx presently has a consensus price target of $72.33, indicating a potential downside of 28.09%. Hims & Hers Health has a consensus price target of $37.31, indicating a potential upside of 0.67%. Given Hims & Hers Health's higher possible upside, analysts clearly believe Hims & Hers Health is more favorable than GeneDx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GeneDx 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Hims & Hers Health 2 Sell rating(s) 7 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.27 Does the media prefer WGS or HIMS? In the previous week, Hims & Hers Health had 13 more articles in the media than GeneDx. MarketBeat recorded 26 mentions for Hims & Hers Health and 13 mentions for GeneDx. GeneDx's average media sentiment score of 1.08 beat Hims & Hers Health's score of 0.72 indicating that GeneDx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeneDx 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Hims & Hers Health 15 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is WGS or HIMS more profitable? Hims & Hers Health has a net margin of 8.19% compared to GeneDx's net margin of -17.12%. Hims & Hers Health's return on equity of 10.97% beat GeneDx's return on equity.Company Net Margins Return on Equity Return on Assets GeneDx-17.12% 3.33% 1.69% Hims & Hers Health 8.19%10.97%8.29% Do institutionals & insiders have more ownership in WGS or HIMS? 61.7% of GeneDx shares are owned by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are owned by institutional investors. 27.3% of GeneDx shares are owned by company insiders. Comparatively, 17.7% of Hims & Hers Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has preferable valuation and earnings, WGS or HIMS? Hims & Hers Health has higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Hims & Hers Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGeneDx$305.45M9.24-$175.77M-$1.96-51.32Hims & Hers Health$1.48B5.58-$23.55M$0.5468.63 Does the MarketBeat Community prefer WGS or HIMS? Hims & Hers Health received 32 more outperform votes than GeneDx when rated by MarketBeat users. However, 47.83% of users gave GeneDx an outperform vote while only 37.07% of users gave Hims & Hers Health an outperform vote. CompanyUnderperformOutperformGeneDxOutperform Votes1147.83% Underperform Votes1252.17% Hims & Hers HealthOutperform Votes4337.07% Underperform Votes7362.93% Which has more risk & volatility, WGS or HIMS? GeneDx has a beta of 1.91, meaning that its stock price is 91% more volatile than the S&P 500. Comparatively, Hims & Hers Health has a beta of 1.37, meaning that its stock price is 37% more volatile than the S&P 500. SummaryHims & Hers Health beats GeneDx on 12 of the 18 factors compared between the two stocks. Remove Ads Get GeneDx News Delivered to You Automatically Sign up to receive the latest news and ratings for WGS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart WGS vs. The Competition Export to ExcelMetricGeneDxHealth services IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.82B$880.69M$5.68B$8.32BDividend YieldN/A2.41%4.55%4.02%P/E Ratio-51.3247.0924.5519.25Price / Sales9.243.64395.7294.09Price / CashN/A26.1438.1634.64Price / Book11.462.797.064.46Net Income-$175.77M-$5.50M$3.19B$247.07M7 Day Performance10.79%1.84%1.49%3.05%1 Month Performance4.95%-5.97%5.87%-2.85%1 Year Performance1,086.20%84.46%14.94%4.63% GeneDx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)WGSGeneDx2.6654 of 5 stars$100.59-2.5%$72.33-28.1%+1,086.2%$2.82B$305.45M-51.321,200Positive NewsHIMSHims & Hers Health2.4299 of 5 stars$34.68+4.6%$37.23+7.4%+127.2%$7.70B$1.48B78.821,046Positive NewsOPCHOption Care Health4.2259 of 5 stars$33.89+3.8%$33.00-2.6%+7.5%$5.60B$5.00B28.485,600Positive NewsGHGuardant Health3.8066 of 5 stars$42.90+0.0%$48.40+12.8%+171.2%$5.29B$739.02M-12.051,790News CoveragePositive NewsRDNTRadNet4.1642 of 5 stars$49.02+5.3%$76.75+56.6%+7.8%$3.63B$1.83B-700.198,970Analyst ForecastHigh Trading VolumeSHCSotera Health2.8181 of 5 stars$11.93+2.9%$15.92+33.4%+1.5%$3.38B$1.10B47.723,000Positive NewsSGRYSurgery Partners2.7955 of 5 stars$24.40+3.4%$36.63+50.1%-15.4%$3.11B$3.11B-50.8313,500Analyst ForecastBTSGBrightSpring Health Services2.4602 of 5 stars$17.45+0.2%$21.67+24.2%+92.2%$3.05B$11.27B-67.1235,000PRVAPrivia Health Group3.9097 of 5 stars$23.24-2.1%$26.67+14.7%+19.2%$2.80B$1.74B232.421,102News CoverageCONConcentra Group Holdings ParentN/A$21.04+1.2%$28.38+34.8%N/A$2.68B$1.90B13.9411,000LFSTLifeStance Health Group2.2127 of 5 stars$6.89-0.4%$8.63+25.2%+12.1%$2.65B$1.25B-26.509,325 Remove Ads Related Companies and Tools Related Companies HIMS Competitors OPCH Competitors GH Competitors RDNT Competitors SHC Competitors SGRY Competitors BTSG Competitors PRVA Competitors CON Competitors LFST Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:WGS) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredHere’s Why Tesla Insiders are Dumping SharesTesla has been on a losing streak ever since Elon Musk first visited the White House in early 2025. Our res...Behind the Markets | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeneDx Holdings Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share GeneDx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy WGS Stock Free WGS Stock Alerts